Classification and grading of noninvasive and invasive neoplasms of the urothelium

Analytical and Quantitative Cytology and Histology

Volumn 34, Issue 3, 2012, Pages 111-119

  Mazzucchelli, Roberta ^a   Cheng, Liang ^b   Lopez Beltran, Antonio ^c   Scarpelli, Marina ^a   Montironi, Rodolfo ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OSPEDALI RIUNITI   (Italy)

Author keywords

Inverted neoplasms; Inverted papilloma; Urothelial carcinoma; Urothelial neoplasms; Urothelium

Indexed keywords

ACCURACY; ARTICLE; CANCER GRADING; CANCER INVASION; CARCINOMA IN SITU; CYTOLOGY; DYSPLASIA; EVALUATION; HUMAN; HYPERPLASIA; PAPILLARY CARCINOMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TUMOR CLASSIFICATION; TUMOR GROWTH; URINARY TRACT TUMOR; UROTHELIAL CARCINOMA IN SITU; UROTHELIAL DYSPLASIA; UROTHELIAL HYPERPLASIA; UROTHELIUM TUMOR;

CARCINOMA, TRANSITIONAL CELL; HUMANS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; URINARY BLADDER NEOPLASMS;

EID: 84865089113     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Montironi R, Mazzucchelli R, Scarpelli M, Lopez-Beltran A, Cheng L Morphological diagnosis of urothelial neoplasms. J Clin Pathol 2008;61:3-10
2. Amin MB, Gómez JA, Young RH Urothelial transitional cell carcinoma with endophytic growth patterns: A discussion of patterns of invasion and problems associated with assessment of invasion in 18 cases. Am J Surg Pathol 1997;21:1057-1068
3. Hodges KB, Lopez-Beltran A, Davidson DD, Montironi R, Cheng L Urothelial dysplasia and other flat lesions of the urinary bladder: Clinicopathologic and molecular features. Hum Pathol 2010;41:155-162
4. Montironi R, Lopez-Beltran A, Scarpelli M, Mazzucchelli R, Cheng L Morphological classification and definition of benign, preneoplastic and non-invasive neoplastic lesions of the urinary bladder. Histopathology 2008;53:621-633
5. Cheng L, Cheville JC, Neumann RM, Bostwick DG Natural history of urothelial dysplasia of the bladder. Am J Surg Pathol 1999;23:443-447
6. Birkhahn M, Mitra AP, Williams AJ, Lam G, Ye W, Datar RH, Balic M, Groshen S, Steven KE, Cote RJ Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. Eur Urol 2010;57:12-20
7. Burger M Editorial comment on: Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: A multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur Urol 2010;57:858
8. Guey LT, García-Closas M, Murta-Nascimento C, Lloreta J, Palencia L, Kogevinas M, Rothman N, Vellalta G, Calle ML, Marenne G, Tardón A, Carrato A, García-Closas R, Serra C, Silverman DT, Chanock S, Real FX, Malats N EPICURO/Spanish Bladder Cancer Study investigators: Genetic susceptibility to distinct bladder cancer subphenotypes. Eur Urol 2010;57:283-292
9. May M, Brookman-Amissah S, Roigas J, Hartmann A, Störkel S, Kristiansen G, Gilfrich C, Borchardt R, Hoschke B, Kaufmann O, Gunia S Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: A multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur Urol 2010;57:850-858
10. van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, Witjes JA, Zlotta AR Recurrence and progression of disease in non-muscle-invasive bladder cancer: From epidemiology to treatment strategy. Eur Urol 2009;56:430-442
11. Yorukoglu K, Tuna B, Kirkali Z: Re: Matthias May, Sabine Brookman-Amissah, Jan Roigas, et al. Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: A multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Comment on Eur Urol 2010;57:850-858. Eur Urol 2010;58:e7
12. Cheng L, Montironi R, Davidson DD, Lopez-Beltran A Staging and reporting of urothelial carcinoma of the urinary bladder. Mod Pathol 2009;22:S70-95
13. Lopez-Beltran A, Cheng L, Andersson L, Brausi M, de Matteis A, Montironi R, Sesterhenn I, van det Kwast KT, Mazerolles C Preneoplastic non-papillary lesions and conditions of the urinary bladder: An update based on the Ancona International Consultation. Virchows Arch 2002;440:3-11
14. Levi AW, Potter SR, Schoenberg MP, Epstein JI Clinical significance of denuded urothelium in bladder biopsy. J Urol 2001;166:457-460
15. Owens CL, Epstein JI Significance of denuded urothelium in papillary urothelial lesions. Am J Surg Pathol 2007;31:298-303
16. Lopez-Beltran A, Luque RJ, Mazzucchelli R, Scarpelli M, Montironi R Changes produced in the urothelium by traditional and newer therapeutic procedures for bladder cancer. J Clin Pathol 2002;55:641-647
17. Baker PM, Young RH Radiation-induced pseudocarcinomatous proliferations of the urinary bladder: A report of 4 cases. Hum Pathol 2000;31:678-683
18. Chan TY, Epstein JI Radiation or chemotherapy cystitis with "pseudocarcinomatous" features. Am J Surg Pathol 2004;28: 909-913
19. Lane Z, Epstein JI Pseudocarcinomatous epithelial hyperplasia in the bladder unassociated with prior irradiation or chemotherapy. Am J Surg Pathol 2008;32:92-97
20. Herawi M, Parwani AV, Chan T, Ali SZ, Epstein JI Polyoma virus-associated cellular changes in the urine and bladder biopsy samples: A cytohistologic correlation. Am J Surg Pathol 2006;30:345-350
21. Taylor DC, Bhagavan BS, Larsen MP, Cox JA, Epstein JI Papillary urothelial hyperplasia: A precursor to papillary neoplasms. Am J Surg Pathol 1996;20:1481-1488
22. Readal N, Epstein JI Papillary urothelial hyperplasia: Relationship to urothelial neoplasms. Pathology 2010;42:360-363
23. Lee TK, Chaux A, Karram S, Miyamoto H, Miller JS, Fajardo DA, Epstein JI, Netto GJ Papillary urothelial neoplasm of low malignant potential of the urinary bladder: Clinicopathologic and outcome analysis from a single academic center. Hum Pathol 2011;42:1799-1803
24. Babjuk M Second resection for non-muscle-invasive bladder carcinoma: Current role and future perspectives. Eur Urol 2010;58:191-192
25. Dalbagni G, Vora K, Kaag M, Cronin A, Bochner B, Donat SM, Herr HW Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur Urol 2009;56:903-910
26. Divrik RT, Sahin AF, Ergör G Reply from authors re: Marko Babjuk: Second resection for non-muscle-invasive bladder carcinoma: Current role and future perspectives. Eur Urol 2010;58:191-192 and Giacomo Novara, Vincenzo Ficarra: Does routine second transurethral resection affect the longterm outcome of patients with T1 bladder cancer? Why a flawed randomized controlled trial cannot address the issue. Eur Urol 2010;58:193-194. Eur Urol 2010;58:195-196
27. Divrik RT, Sahin AF, Yildirim U, Altok M, Zorlu F Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: A prospective randomised clinical trial. Eur Urol 2010;58:185-190
28. Fritsche HM, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G, Skinner E, Denzinger S, Fradet Y, Isbarn H, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Tilki D, Otto W, Capitanio U, Izawa JI, Ficarra V, Lerner S, Sagalowsky AI, Schoenberg M, Kamat A, Dinney CP, Lotan Y, Shariat SF Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: Results from an international cohort. Eur Urol 2010;57:300-309
29. Kulkarni GS, Hakenberg OW, Gschwend JE, Thalmann G, Kassouf W, Kamat A, Zlotta A An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol 2010;57:60-70
30. Lopez-Beltran A, Algaba F, Berney DM, Boccon-Gibod L, Camparo P, Griffiths D, Mikuz G, Montironi R, Varma M, Egevad L Handling and reporting of transurethral resection specimens of the bladder in Europe: A web-based survey by the European Network of Uropathology (ENUP). Histopathology 2011;58:579-585
31. Novara G, Ficarra V Does routine second transurethral resection affect the long-term outcome of patients with T1 bladder cancer? Why a flawed randomized controlled trial cannot address the issue. Eur Urol 2010;58:193-194
32. Otto W, Denzinger S, Fritsche HM, Burger M, Wieland WF, Hofstädter F, Hartmann A, Bertz S The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer. BJU Int 2011;107:404-408
33. van Rhijn BW, Zuiverloon TC, Vis AN, Radvanyi F, van Leenders GJ, Ooms BC, Kirkels WJ, Lockwood GA, Boevé ER, Jöbsis AC, Zwarthoff EC, van der Kwast TH Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol 2010;58:433-441
34. Billis A, Carvalho RB, Mattos AC, Negretti F, Nogueira CR, Oliveira MC, Valença JT Jr, Adam RL, Cotta AC, Nunes MS, Dinamarco PV Tumor grade heterogeneity in urothelial bladder carcinoma: Proposal of a system using combined numbers. Scand J Urol Nephrol 2001;35:275-279
35. Bircan S, Candir O, Serel TA Comparison of WHO 1973, WHO/ISUP 1998, WHO 1999 grade and combined scoring systems in evaluation of bladder carcinoma. Urol Int 2004;73: 201-208
36. Cheng L, Neumann RM, Nehra A, Spotts BE, Weaver AL, Bostwick DG Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma. Cancer 2000;88: 1663-1670
37. Krüger S, Thorns C, Böhle A, Feller AC Prognostic significance of a grading system considering tumor heterogeneity in muscle-invasive urothelial carcinoma of the urinary bladder. Int Urol Nephrol 2003;35:169-173
38. Epstein JI, Amin MB, Reuter VR, Mostofi FK The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998;22:1435-1448
39. Cheng L, Bostwick DG Overdiagnosis of bladder carcinoma. Anal Quant Cytol Histol 2008;30:261-264
40. Lott S, Wang M, Zhang S, MacLennan GT, Lopez-Beltran A, Montironi R, Sung MT, Tan PH, Cheng L FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: Incidence and etiological considerations. Mod Pathol 2009;22: 627-632
41. Sung MT, Maclennan GT, Lopez-Beltran A, Montironi R, Cheng Lc Natural history of urothelial inverted papilloma. Cancer 2006;107:2622-2627
42. Cheng L, Lopez-beltran A, MacLennan GT, Montironi R, Bostwick DG Neoplasms of the urinary bladder. In Urologic Surgical Pathology. Edited by DG Bostwick, L Cheng. Philadelphia, Mosby/Elsevier, 2008, pp 289-292
43. Hodges KB, Lopez-Beltran A, Maclennan GT, Montironi R, Cheng L Urothelial lesions with inverted growth patterns: Histogenesis, molecular genetic findings, differential diagnosis and clinical management. BJU Int 2011;107:532-537
44. Jones TD, Zhang S, Lopez-Beltran A, Eble JN, Sung MT, MacLennan GT, Montironi R, Tan PH, Zheng S, Baldridge LA, Cheng L Urothelial carcinoma with an inverted growth pattern can be distinguished from inverted papilloma by fluorescence in situ hybridization, immunohistochemistry, and morphologic analysis. Am J Surg Pathol 2007;31:1861-1867
45. Epstein JI, Amin MB Urothelial neoplasms with inverted growth patterns. In Biopsy Interpretation of the Bladder. Edited by JI Epstein, MB Amin. Philadelphia, Lippincott Williams & Wilkins, 2010, pp 79-93
46. McKenney JK, Vankalakunti M Overview of urinary bladder neoplasms. In Diagnostic Pathology: Genitourinary. Edited by MB Amin. Manitoba, AMIRSYS, 2010, pp 50-51